XTalks
MAY 22, 2023
Conscious Greens is the first offering from Pairwise’s new brand, Conscious Foods. Pairwise teamed up with Performance Food Group (PFG) to co-brand its Purple Power Baby Greens Blend under PFG’s Peak Fresh Produce premium brand. Paul region, St. Louis and Springfield, Massachusetts.
pharmaphorum
OCTOBER 12, 2022
This need for data integrity facilitates and maintains trust between the regulators and the manufacturing organisations and, in turn, patients. However, as necessary as data is, it has ironically been sighted as one of the top concerns related to the issuing of observation notices and warning letters by regulators. About the author.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 30, 2021
This strategic partnership combines Teva’s long-standing commercial presence, extensive distribution network and wide-reaching sales and marketing activities across Europe and international markets with Bioeq’s capabilities in the development of biosimilar drugs for highly regulated countries with stringent quality standards.
pharmaphorum
JANUARY 8, 2021
The deal gives Angelini an exclusive European license to market cenobamate, a drug being developed for drug-resistant focal-onset seizures in adults. The license covers the European Union and other countries in the European Economic Area, such as Switzerland and the UK. It is a small molecule with a dual action, which stimulates the
Pharmacy Checkers
JANUARY 10, 2020
A friend of mine, who has very difficult to control cholesterol, was prescribed Livalo, an FDA-approved brand of the drug pitavastatin. He went to our site to discover that brand-name Livalo ( pitavastatin ). He went to our site to discover that brand-name Livalo ( pitavastatin ). Let’s call him John. Is the drug safe?
pharmaphorum
APRIL 6, 2022
The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the drug due in July. billion in milestones, shortly after its own PD-1 drug candidate spartalizumab failed a phase 3 trial in melanoma.
XTalks
JANUARY 29, 2021
This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g. Celltrion’s Herceptin biosimilar, Truxima).
Expert insights. Personalized for you.
98 
Let's personalize your content